News

Zacks Investment Research on MSN1d
Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down
Shares of Prothena PRTA tumbled 22.5% in after-hours trading on May 23 after it announced the discontinuation of the ...
Investment Case For Eli Lilly Still Weak, Despite Novo Nordisk's Struggle
Eli Lilly's growth is impressive, but its current valuation is only justifiable with sustained high growth. Click here to ...
Barron's5d
Novo Nordisk A/S ADR
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity ...
Novo Nordisk's former chief makes comeback to steer choice of new CEO
Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars Rebien Sorensen told a press ...